

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 8-K**

---

**Current Report  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 19, 2016**

---

**Corcept Therapeutics Incorporated**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-50679**  
(Commission  
File Number)

**77-0487658**  
(I.R.S. Employer  
Identification No.)

**149 Commonwealth Drive**  
**Menlo Park, CA 94025**  
(Address of principal executive offices, with zip code)

**(650) 327-3270**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## Item 5.07 Submission of Matters to a Vote of Security Holders

On May 19, 2016, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect seven directors to hold office until our 2017 annual meeting of stockholders and until their successors are elected and qualified, and 2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.

A total of 109,710,939 shares of Corcept common stock held by stockholders of record at the close of business on April 8, 2016 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 103,229,513. The voting on the two matters is set forth below:

Proposal 1 – Election of Directors. The following directors were elected to serve until our 2017 annual meeting of stockholders and until their successors are elected.

Director:	For	Withheld	Broker Non-Votes
G. Leonard Baker, Jr.	71,279,606	3,320,003	28,629,904
Joseph K. Belanoff, M.D.	74,007,363	592,246	28,629,904
Daniel M. Bradbury	57,529,377	17,070,232	28,629,904
Patrick G. Enright	73,929,155	670,454	28,629,904
David L. Mahoney	73,887,755	711,854	28,629,904
Daniel N. Swisher, Jr.	59,574,984	15,024,625	28,629,904
James N. Wilson	65,747,905	8,851,704	28,629,904

Proposal 2 – To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.

For	102,079,492
Against	1,142,934
Abstain	7,087
Broker Non-Votes	N/A

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS INCORPORATED**

Date: May 19, 2016

By: /s/ G. Charles Robb

G. Charles Robb

Chief Financial Officer and Secretary